Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. / Petersen, Anne Marie Winther; Magkos, Faidon; Atherton, Philip; Selby, Anna; Smith, Kenneth; Rennie, Michael J; Pedersen, Bente Klarlund; Mittendorfer, Bettina.
In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 293, No. 3, 2007, p. E843-E848.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle
AU - Petersen, Anne Marie Winther
AU - Magkos, Faidon
AU - Atherton, Philip
AU - Selby, Anna
AU - Smith, Kenneth
AU - Rennie, Michael J
AU - Pedersen, Bente Klarlund
AU - Mittendorfer, Bettina
N1 - (Ekstern)
PY - 2007
Y1 - 2007
N2 - Smoking causes multiple organ dysfunction. The effect of smoking on skeletal muscle protein metabolism is unknown. We hypothesized that the rate of skeletal muscle protein synthesis is depressed in smokers compared with non-smokers. We studied eight smokers (> or =20 cigarettes/day for > or =20 years) and eight non-smokers matched for sex (4 men and 4 women per group), age (65 +/- 3 and 63 +/- 3 yr, respectively; means +/- SEM) and body mass index (25.9 +/- 0.9 and 25.1 +/- 1.2 kg/m2, respectively). Each subject underwent an intravenous infusion of stable isotope-labeled leucine in conjunction with blood and muscle tissue sampling to measure the mixed muscle protein fractional synthesis rate (FSR) and whole body leucine rate of appearance (Ra) in plasma (an index of whole body proteolysis), the expression of genes involved in the regulation of muscle mass (myostatin, a muscle growth inhibitor, and MAFBx and MuRF-1, which encode E3 ubiquitin ligases in the proteasome proteolytic pathway) and that for the inflammatory cytokine TNF-alpha in muscle, and the concentration of inflammatory markers in plasma (C-reactive protein, TNF-alpha, interleukin-6) which are associated with muscle wasting in other conditions. There were no differences between nonsmokers and smokers in plasma leucine concentration, leucine rate of appearance, and plasma concentrations of inflammatory markers, or TNF-alpha mRNA in muscle, but muscle protein FSR was much less (0.037 +/- 0.005 vs. 0.059 +/- 0.005%/h, respectively, P = 0.004), and myostatin and MAFBx (but not MuRF-1) expression were much greater (by approximately 33 and 45%, respectivley, P < 0.05) in the muscle of smokers than of nonsmokers. We conclude that smoking impairs the muscle protein synthesis process and increases the expression of genes associated with impaired muscle maintenance; smoking therefore likely increases the risk of sarcopenia.
AB - Smoking causes multiple organ dysfunction. The effect of smoking on skeletal muscle protein metabolism is unknown. We hypothesized that the rate of skeletal muscle protein synthesis is depressed in smokers compared with non-smokers. We studied eight smokers (> or =20 cigarettes/day for > or =20 years) and eight non-smokers matched for sex (4 men and 4 women per group), age (65 +/- 3 and 63 +/- 3 yr, respectively; means +/- SEM) and body mass index (25.9 +/- 0.9 and 25.1 +/- 1.2 kg/m2, respectively). Each subject underwent an intravenous infusion of stable isotope-labeled leucine in conjunction with blood and muscle tissue sampling to measure the mixed muscle protein fractional synthesis rate (FSR) and whole body leucine rate of appearance (Ra) in plasma (an index of whole body proteolysis), the expression of genes involved in the regulation of muscle mass (myostatin, a muscle growth inhibitor, and MAFBx and MuRF-1, which encode E3 ubiquitin ligases in the proteasome proteolytic pathway) and that for the inflammatory cytokine TNF-alpha in muscle, and the concentration of inflammatory markers in plasma (C-reactive protein, TNF-alpha, interleukin-6) which are associated with muscle wasting in other conditions. There were no differences between nonsmokers and smokers in plasma leucine concentration, leucine rate of appearance, and plasma concentrations of inflammatory markers, or TNF-alpha mRNA in muscle, but muscle protein FSR was much less (0.037 +/- 0.005 vs. 0.059 +/- 0.005%/h, respectively, P = 0.004), and myostatin and MAFBx (but not MuRF-1) expression were much greater (by approximately 33 and 45%, respectivley, P < 0.05) in the muscle of smokers than of nonsmokers. We conclude that smoking impairs the muscle protein synthesis process and increases the expression of genes associated with impaired muscle maintenance; smoking therefore likely increases the risk of sarcopenia.
KW - Aged
KW - Down-Regulation/physiology
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Muscle Proteins/metabolism
KW - Muscle, Skeletal/metabolism
KW - Myostatin
KW - Protein Biosynthesis/physiology
KW - SKP Cullin F-Box Protein Ligases/metabolism
KW - Smoking/metabolism
KW - Transforming Growth Factor beta/metabolism
KW - Muscle growth
KW - Stable-isotope-labeled tracers
KW - Sarcopenia
KW - Protein turnover
U2 - 10.1152/ajpendo.00301.2007
DO - 10.1152/ajpendo.00301.2007
M3 - Journal article
C2 - 17609255
VL - 293
SP - E843-E848
JO - American Journal of Physiology - Endocrinology and Metabolism
JF - American Journal of Physiology - Endocrinology and Metabolism
SN - 0193-1849
IS - 3
ER -
ID: 297125188